DESTINY-PANTUMOUR04

Recruiting now

Conditions studied: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer

In brief

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

Key facts

Study ID

NCT07124000

Run by

AstraZeneca

People needed

100

Starts

2025-09-18

Expected to finish

2028-03-30

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged ≥18 years
• Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);
• A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;
• HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;
• Patients who are willing and able to provide a signed and dated informed consent.

You may not qualify if…

• Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;
• Prior T-DXd therapy;
• Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.
• Patient is participating in a clinical trial at time of enrolment

Where it is running

• Research Site — Birmingham, Alabama, United States (enrolling)
• Research Site — Bullhead City, Arizona, United States (enrolling)
• Research Site — Casa Grande, Arizona, United States (enrolling)
• Research Site — San Diego, California, United States (enrolling)
• Research Site — Boulder, Colorado, United States (enrolling)
• Research Site — Coral Springs, Florida, United States (enrolling)
• Research Site — St. Petersburg, Florida, United States (enrolling)
• Research Site — West Palm Beach, Florida, United States (enrolling)
• Research Site — Decatur, Illinois, United States (enrolling)
• Research Site — Topeka, Kansas, United States (enrolling)
• Research Site — Farmington, New Mexico, United States (enrolling)
• Research Site — Durham, North Carolina, United States (enrolling)
• Research Site — Wilson, North Carolina, United States (enrolling)
• Research Site — Canton, Ohio, United States (enrolling)
• Research Site — Maumee, Ohio, United States (enrolling)
• Research Site — Philadelphia, Pennsylvania, United States (enrolling)
• Research Site — Nashville, Tennessee, United States (enrolling)
• Research Site — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.